Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Other Events

Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Other Events
Item 8.01   Other Information

On June 22, 2020, Heat Biologics, Inc. (the “Company”) issued a press release announcing that its Pelican Therapeutics subsidiary (“Pelican”) has dosed the first patient in its Phase 1 clinical trial of Pelican’s PTX-35 monoclonal antibody. This trial is supported by a $15.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is filed with this Current Report on Form 8-K.

  


HEAT BIOLOGICS, INC. Exhibit
EX-99.1 2 htbx_ex99z1.htm PRESS RELEASE Press Release   EXHIBIT 99.1 Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35 Durham,…
To view the full exhibit click here

Story continues below

About Heat Biologics, Inc. (NASDAQ:HTBX)

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

An ad to help with our costs